Radioprotection by the Histone Deacetylase Inhibitor Phenylbutyrate

Overview

Journal Radiat Environ Biophys

Specialties Biophysics
Environmental Health
Oncology
Radiology

Date 2011 Sep 6

PMID 21892632

Citations 19

Authors

Alexandra C Miller

Stuart Cohen

Michael Stewart

Rafael Rivas

Paul Lison

Affiliations

Soon will be listed here.

Abstract

The histone deacetylase inhibitor (HDAC), phenylbutyrate (PB), is a novel anti-tumor agent. Studies have demonstrated that HDAC inhibitors can suppress cutaneous radiation syndrome and stimulate hematopoiesis. The objective of this study was to test the ability of PB treatment to protect against acute gamma-radiation-induced lethality in the DBA/2 mouse model. A 30-day radiation lethality study was used to assess radioprotective capability of PB. Mechanisms were evaluated using western blots, flow cytometry, and the single-cell gel electrophoresis assay. Western blot studies showed that PB treatment acetylated histones in vivo. For radiation protection studies, prophylactic administration of PB (24 h preradiation; 1-50 mg/kg) provided radioprotection against gamma radiation (8-9.5 Gy) and PB demonstrated a DRF of 1.31 (P = 0.001; 95% confidence interval: 1.27, 1.36). When PB (10 mg/kg) was administered post-radiation (4 h), it also provided significant radioprotection at 8.0 Gy radiation (P = 0.022). PB treatment before radiation was associated with significant elevations in neutrophils and platelets following radiation. Results from single-cell gel electrophoresis of peripheral blood leukocytes demonstrated that PB treatment before radiation can attenuate DNA damage and inhibit radiation-induced apoptosis. These results indicate that an HDAC inhibitor like PB has potential as a radiation protector and that mechanisms of action include attenuation of DNA damage and inhibition of apoptosis.

Citing Articles

Valproic acid as a radio-sensitizer in glioma: A systematic review and meta-analysis.

Sullivan J, Fahey P, Agho K, Hurley S, Feng Z, Day R Neurooncol Pract. 2023; 10(1):13-23.

PMID: 36659976 PMC: 9837785. DOI: 10.1093/nop/npac078.

4-PBA Treatment Improves Bone Phenotypes in the Aga2 Mouse Model of Osteogenesis Imperfecta.

Duran I, Zieba J, Csukasi F, Martin J, Wachtell D, Barad M J Bone Miner Res. 2022; 37(4):675-686.

PMID: 34997935 PMC: 9018561. DOI: 10.1002/jbmr.4501.

Endoplasmic reticulum stress and pulmonary hypertension.

Hu Y, Yang W, Xie L, Liu T, Liu H, Liu B Pulm Circ. 2020; 10(1):2045894019900121.

PMID: 32110387 PMC: 7000863. DOI: 10.1177/2045894019900121.

4-Phenylbutyric Acid Reduces Endoplasmic Reticulum Stress in Chondrocytes That Is Caused by Loss of the Protein Disulfide Isomerase ERp57.

Rellmann Y, Gronau I, Hansen U, Dreier R Oxid Med Cell Longev. 2019; 2019:6404035.

PMID: 31781343 PMC: 6875354. DOI: 10.1155/2019/6404035.

Efficacy of Azatyrosine-Phenylbutyric Hydroxamides, a Histone Deacetylase Inhibitor, on Chemotherapy-Induced Gastrointestinal Mucositis.

Liao P, Huang S, Hung C, Huang W, Tsai C, Kang J Int J Mol Sci. 2019; 20(2).

PMID: 30634582 PMC: 6359543. DOI: 10.3390/ijms20020249.

References

Hafer N, Maidment B, Hatchett R . The NIAID Radiation Countermeasures Program business model. Biosecur Bioterror. 2010; 8(4):357-63. PMC: 3011992. DOI: 10.1089/bsp.2010.0041. View

Samid D, Shack S, Sherman L . Phenylacetate: a novel nontoxic inducer of tumor cell differentiation. Cancer Res. 1992; 52(7):1988-92. View

Prasanna P, Thibault A, Liu L, Samid D . Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells. J Neurochem. 1996; 66(2):710-6. DOI: 10.1046/j.1471-4159.1996.66020710.x. View

Pace B, White G, Dover G, Boosalis M, Faller D, Perrine S . Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood. 2002; 100(13):4640-8. PMC: 4269367. DOI: 10.1182/blood-2002-02-0353. View

Chung Y, Lee M, Pui N . Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis. Carcinogenesis. 2009; 30(8):1387-97. DOI: 10.1093/carcin/bgp079. View

Han S, Wada R, Sidell N . Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. Cancer Res. 2001; 61(10):3998-4002. View

Brown S, Kolozsvary A, Liu J, Ryu S, Kim J . Histone deacetylase inhibitors protect against and mitigate the lethality of total-body irradiation in mice. Radiat Res. 2008; 169(4):474-8. PMC: 2802131. DOI: 10.1667/RR1245.1. View

Samid D, Ram Z, Hudgins W, Shack S, Liu L, Walbridge S . Selective activity of phenylacetate against malignant gliomas: resemblance to fetal brain damage in phenylketonuria. Cancer Res. 1994; 54(4):891-5. View

Resar L, Segal J, Fitzpatric L, Friedmann A, Brusilow S, Dover G . Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol Oncol. 2002; 24(9):737-41. DOI: 10.1097/00043426-200212000-00011. View

10.

Paoluzzi L, Figg W . Histone deacetylase inhibitors are potent radiation protectants. Cancer Biol Ther. 2004; 3(7):612-3. DOI: 10.4161/cbt.3.7.931. View

11.

Whitnall M, Inal C, Jackson 3rd W, Miner V, Villa V, Seed T . In vivo radioprotection by 5-androstenediol: stimulation of the innate immune system. Radiat Res. 2001; 156(3):283-93. DOI: 10.1667/0033-7587(2001)156[0283:ivrbas]2.0.co;2. View

12.

Lopez C, Feng F, Herman J, Nyati M, Lawrence T, Ljungman M . Phenylbutyrate sensitizes human glioblastoma cells lacking wild-type p53 function to ionizing radiation. Int J Radiat Oncol Biol Phys. 2007; 69(1):214-20. DOI: 10.1016/j.ijrobp.2007.04.069. View

13.

Seed T, Kumar S, Whitnall M, Srinivasan V, Singh V, Elliott T . New strategies for the prevention of radiation injury: possible implications for countering radiation hazards of long-term space travel. J Radiat Res. 2003; 43 Suppl:S239-44. DOI: 10.1269/jrr.43.s239. View

14.

Liu L, Hudgins W, Miller A, Chen L, Samid D . Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Cytokine. 1995; 7(5):449-56. DOI: 10.1006/cyto.1995.0061. View

15.

Samid D, Wells M, Greene M, Shen W, Palmer C, Thibault A . Peroxisome proliferator-activated receptor gamma as a novel target in cancer therapy: binding and activation by an aromatic fatty acid with clinical antitumor activity. Clin Cancer Res. 2000; 6(3):933-41. View

16.

Fibach E, Prasanna P, Rodgers G, Samid D . Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. Blood. 1993; 82(7):2203-9. View

17.

Zaskodova D, Rezacova M, Vavrova J, Vokurkova D, Tichy A . Effect of valproic acid, a histone deacetylase inhibitor, on cell death and molecular changes caused by low-dose irradiation. Ann N Y Acad Sci. 2007; 1091:385-98. DOI: 10.1196/annals.1378.082. View

18.

Nubel T, Damrot J, Roos W, Kaina B, Fritz G . Lovastatin protects human endothelial cells from killing by ionizing radiation without impairing induction and repair of DNA double-strand breaks. Clin Cancer Res. 2006; 12(3 Pt 1):933-9. DOI: 10.1158/1078-0432.CCR-05-1903. View

19.

Jung M . Inhibitors of histone deacetylase as new anticancer agents. Curr Med Chem. 2001; 8(12):1505-11. DOI: 10.2174/0929867013372058. View

20.

Samid D, Shack S, Myers C . Selective growth arrest and phenotypic reversion of prostate cancer cells in vitro by nontoxic pharmacological concentrations of phenylacetate. J Clin Invest. 1993; 91(5):2288-95. PMC: 288233. DOI: 10.1172/JCI116457. View